DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.47 No.1 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/696

Title: アンジオテンシンⅡ受容体拮抗薬(TCV-116)の心肥大抑制効果 : 自然発症高血圧ラット(SHR)での検討
Other Titles: SUPPRESSIVE EFFECT OF AN ANGIOTENSIN Ⅱ RECEPTOR ANTAGONIST (TCV-116) ON MYOCARDIAL HYPERTROPHY IN SPONTANEOUSLY HYPERTENSIVE RATS (SHR)
Authors: 舛田, 譲二
Keywords: angiotensin Ⅱ receptor antagonist
cardiac fibrosis
cardiac hypertrophy
hypertension
spontaneously hypertensive rat(SHR)
Issue Date: 29-Feb-1996
Publisher: 奈良医学会
Citation: 奈良医学雑誌 Vol.47 No.1 p.26-37
Abstract: The renin-angiotensin system is an important hormonal system that regu- lates volume and fluid homeostasis. Recently, it has been suggested that angiotensinⅡ (A Ⅱ)may directly cause cardiac hypertrophy and fibrosis by acting on myocardial cells. I investigated the preventive effect of an AⅡ reseptor antagonist(TCV-116)on the develop- ment of cardiac hypertrophy and fibrosis in spontaneously hypertensive rats(SHR) at 16 and 24 weeks of age through histopathological study, an AⅡ receptor assay and studies of type -1 angiotensin Ⅱ (AT-1)receptor messenger RNA(mRNA)expression. AⅡ receptor den- sity was determined by radiobinding immunoassay. The expression of AⅡ receptor mRNA in myocardial cells was determined by reverse transcriptase-polymerase chain reaction(rt -PCR). The groups of treatment with TCV-116, ACE inhibitor(enalapril)and hydralazine at 8, 16 and 24 weeks of age showed significantly lower systolic blood pressure than the no treatment group. The heart weight/ body weight ratio, the diameter of myocardium and the percent area of myocardial fibrosis were significantly lower in the group of treatment with enalapril and TCV-116 than the group of treatment with hydralazine and non medicated SHR at 16 and 24 weeks of age. The density of AⅡ receptor and the expression of AT-1 receptor mRNA were significantly higher in the group of treatment with enalapril and TCV-116 than the group of treatment with hydralazine and non medicated SHR at 24 weeks of age. The present study suggests that angiotensin Ⅱ may be involved in the development of cardiac hypertrophy and fibrosis in SHR, and that the AⅡ receptor antagonist inhibited the progression of cardiac hypertrophy and fibrosis via the AⅡ receptor, and that the density of AⅡ receptor and the expression of AT-1 receptor mRNA may be regulated by the stimulus to AⅡ receptor.
URI: http://hdl.handle.net/10564/696
ISSN: 04695550
13450069
Appears in Collections:Vol.47 No.1

Files in This Item:

File Description SizeFormat
026-037p.アンジオテンシンⅡ受容体拮抗薬(TCV-116)の心肥大抑制効果.pdf5.36 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback